# A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

> **NCT07690319** · — · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 186 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07690319
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-15
- **Primary completion:** 2027-03-15
- **Final completion:** 2027-03-15
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690319, "A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07690319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*